Cyril Catelain

Cyril Catelain

Auto-generated profile, based on publicly available information

Cyril Catelain

Universite Paris-Saclay, INSERM, Gustave Roussy Cancer Center, Villejuif - France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell
Verified
Journal Article
Closed access
ASAymeric Silvin
Aymeric Silvin
Nicolas ChapuisNicolas Chapuis
Nicolas Chapuis
GDGarett Dunsmore
Garett Dunsmore
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
ADAgathe Dubuisson
Agathe Dubuisson
ESEric Solary
Eric Solary

19 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NDNicolas Deredec
Nicolas Deredec
LALisa Aziez
Lisa Aziez
IBIsmael Boussaid
Ismael Boussaid
JDJustine Decroocq
Justine Decroocq
AGAxelle Guedon
Axelle Guedon
YSYannick Simoni
Yannick Simoni
The emergence of bispecific antibodies (BsAbs) targeting T cells (CD3+) and tumor plasma B cells (BCMA+) has provided a new therapeutic option for patients with relapsed/refractory multiple myeloma cancer. However, responses to CD3xBCMA BsAb therapy remain heterogeneous, and treatment is associated with frequent immune-related adverse events. Although baseline immune characteristics have been associated with clinical outcomes, little is known about the early immune dynamics induced by this therapy. Here, we investigated whether longitudinal clinical monitoring and high-dimensional profiling of blood circulating T cells could identify early biomarkers of response or toxicity during treatment. Our results indicate that all treated patients exhibit an early depletion of circulating T cells associated with T-cell activation within the first two weeks. Integration of clinical and immunological parameters using Factorial Analysis of Mixed Data (FAMD) identified immune features associated with treatment outcome. Responders had lower plasma soluble BCMA concentrations, fewer bone lesions, higher circulating lymphocyte counts at baseline. During the first days of treatment, responders exhibited a more pronounced increase in plasma CXCL10 levels, associated with a greater decrease in T lymphocyte counts. Overall, our findings suggest that integrating clinical and immune parameters measured during the first days of treatment may enable early patient stratification and support the development of a predictive score to identify patients with multiple myeloma who are most likely to benefit from CD3xBCMA BsAb therapy.

17 September 2020 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
JEJessy Etienne
Jessy Etienne
PJPierre Joanne
Pierre Joanne
CCCyril Catelain
Cyril Catelain
SRStéphanie Riveron
Stéphanie Riveron
AWAlexandra Bayer Wildberger
Alexandra Bayer Wildberger
JVJean‐Thomas Vilquin
Jean‐Thomas Vilquin
Click on the article title to read more.